Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood protein levels may predict stroke outcomes

NCT ID NCT07513428

Knowledge-focused Sponsor: The First Hospital of Jilin University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 79 people who had a stroke to see if levels of a protein called PrPC in their blood were linked to how severe the stroke was and how well they recovered. Researchers collected blood samples and checked patients' health 3 months later. No treatments were tested—the goal was simply to learn more about the role of this protein in stroke.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

79 people

The number who actually took part.

Started

Jun 2023

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years were consecutively enrolled in this study. For wake-up strokes, onset was defined as last known well. Anterior circulation ischemic stroke patients were defined by infarct location within the ICA-MCA and/or ACA territories on MRI-DWI (supported by CTA/MRA when available).

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years Exclusion Criteria: * (1) patients who received intravenous thrombolysis or endovascular intervention; (2) patients with infectious diseases, autoimmune diseases, or those receiving immunosuppressive or immunomodulatory therapy; (3) patients with a history of cerebral infarction or intracerebral hemorrhage within the past year; (4) patients with severe hepatic or renal dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding three times the upper limit of normal, serum creatinine levels \>265 μmol/L, heart failure, or malignant tumors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute cerebral infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute cerebral infarction

Contacts and locations

Locations

  • The First Hospital of Jilin University

    Changchun, Jilin, 130021, China